3D Tissue Models

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors Review type Summary Keywords File filename File mime type
1. 2011 Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis J Clin Oncol 21(22):4151-6
2. 2011 Lessons From ASH 2010: A Focus on NHL J Natl Compr Canc Netw 9(1):7-11
3. 2010 High-dose chemo-radiotherapy for relapsed or refractory hodgkin lymphoma and the significance of pre-transplant functional imaging Br J Haematol
4. 2010 Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma J Clin Oncol 28(11):1896-903
5. 2010 Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma Blood 116(23):4934-7
6. 2010 A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma Br J Cancer 103(12):1783-7
7. 2010 NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas J Natl Compr Canc Netw 8(3):288-334
8. 2010 Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes Clin Cancer Res 16(2):719-26
9. 2010 Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma Ann Oncol 21(1):133-9
10. 2010 Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience Ann Oncol 21(3):574-81
11. 2010 An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma J Natl Compr Canc Netw 8(3):347-52
12. 2009 Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies J Clin Oncol
13. 2009 Follicular lymphoma in the United States: first report of the national LymphoCare study J Clin Oncol 27(8):1202-8
14. 2009 Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation Biol Blood Marrow Transplant 15(12):1538-42
15. 2009 NCCN task force report: molecular markers in leukemias and lymphomas J Natl Compr Canc Netw 7 Suppl 4(S1-34, quiz S5-6
16. 2009 Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project Blood 113(20):4834-40
17. 2009 Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial Br J Haematol 145(1):34-9
18. 2009 Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma Br J Haematol
19. 2009 Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909 J Clin Oncol
20. 2009 Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma Br J Haematol 146(2):158-63
21. 2009 Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses J Clin Oncol 27(4):491-7
22. 2009 The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma Bone Marrow Transplant 43(12):941-8
23. 2008 Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity J Clin Oncol 26(11):1858-64
24. 2008 Synchronous presentation of systemic and brain non-Hodgkin lymphoma Leuk Lymphoma 49(12):2370-3
25. 2008 Hodgkin disease/lymphoma J Natl Compr Canc Netw 6(6):594-622
26. 2008 Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network J Clin Oncol 26(31):5107-12
27. 2008 Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma Clin Adv Hematol Oncol 6(6):437-45
28. 2008 Overview of lymphoma diagnosis and management Radiol Clin North Am 46(2):175-98, vii
29. 2008 A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma Br J Haematol 143(2):201-9
30. 2008 Treatment of follicular lymphoma: current status Leuk Lymphoma 49 Suppl 1(7-17
31. 2008 Lymphoid malignancies: a decade and a half of dramatic improvements in outcome Clin Lymphoma Myeloma 8 Suppl 4(S126-7
32. 2008 Non-Hodgkin's lymphomas J Natl Compr Canc Netw 6(4):356-421
33. 2007 Will radioimmunotherapy survive? Clin Adv Hematol Oncol 5(10):782-4
34. 2007 FDG-PET lymphoma demonstration project invitational workshop Acad Radiol 14(3):330-9
35. 2007 Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804 Ann Oncol 18(6):1071-9
36. 2007 NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer J Natl Compr Canc Netw 5 Suppl 1(S1-S22; quiz S3-2
37. 2007 Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma Br J Haematol 139(3):425-8
38. 2007 Molecular cytogenetic analysis of follicular lymphoma (FL) provides detailed characterization of chromosomal instability associated with the t(14;18)(q32;q21) positive and negative subsets and histologic progression Cytogenet Genome Res 118(2-4):337-44
39. 2007 Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma Ann Oncol 18(11):1842-50
40. 2007 Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine Leuk Lymphoma 48(3):521-5
41. 2007 Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma Cancer 110(11):2528-34
42. 2007 Automated matching and segmentation of lymphoma on serial CT examinations Med Phys 34(1):55-62
43. 2006 Marker-controlled watershed for lymphoma segmentation in sequential CT images Med Phys 33(7):2452-60
44. 2006 Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology J Natl Compr Canc Netw 4(3):258-310
45. 2006 Hodgkin disease/lymphoma. Clinical practice guidelines in oncology J Natl Compr Canc Netw 4(3):210-30
46. 2006 Mantle cell lymphoma: an update on management Ann Oncol 17 Suppl 4(iv12-4
47. 2006 Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma Br J Haematol 134(2):202-7
48. 2006 Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia J Clin Oncol 24(10):1575-81
49. 2006 Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population Ann Oncol 17(6):909-13
50. 2006 Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas Blood 107(6):2477-85
51. 2006 Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies J Clin Oncol 24(1):166-73
52. 2005 R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy Leuk Lymphoma 46(4):541-7
53. 2005 Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas J Clin Oncol 23(30):7565-73
54. 2005 Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography J Clin Oncol 23(21):4652-61
55. 2005 Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma J Clin Oncol 23(4):676-84
56. 2005 Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma Leuk Lymphoma 46(11):1569-73
57. 2005 Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab Blood 105(12):4576-82
58. 2005 Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999 Br J Haematol 130(5):691-9
59. 2005 Gastric mucosa-associated lymphoid tissue lymphoma detected by clonotypic polymerase chain reaction despite continuous pathologic remission induced by involved-field radiotherapy J Clin Oncol 23(16):3768-72
60. 2005 Proteasome inhibitors in non-Hodgkin's lymphoma J Natl Compr Canc Netw 3 Suppl 1(S34-6
61. 2005 Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL Blood 106(10):3383-5
62. 2004 Non-Hodgkin's lymphoma clinical practice guidelines J Natl Compr Canc Netw 2(4):286-336
63. 2004 The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide Ann Oncol 15(10):1495-503
64. 2004 Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease Br J Haematol 125(6):701-8
65. 2004 Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas Blood 103(5):1862-8
66. 2004 Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma Appl Immunohistochem Mol Morphol 12(3):211-5
67. 2004 Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II J Natl Compr Canc Netw 2 Suppl 4(S21-2
68. 2004 Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease Br J Haematol 124(5):645-52
69. 2004 Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease Blood 104(12):3483-9
70. 2004 Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma Blood 103(10):3684-8
71. 2004 The radioisotope contributes significantly to the activity of radioimmunotherapy Clin Cancer Res 10(23):7792-8
72. 2003 Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response J Nucl Med 44(2):260-8
73. 2003 Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma Blood 102(6):1989-96
74. 2003 Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma Bone Marrow Transplant 32(7):673-9
75. 2003 Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma Ann Oncol 14 Suppl 1(i5-10
76. 2003 CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas Leuk Lymphoma 44(6):967-71
77. 2003 MUC-1 mucin protein expression in B-cell lymphomas Appl Immunohistochem Mol Morphol 11(1):28-32
78. 2003 Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression Leuk Lymphoma 44(6):1027-35
79. 2003 Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma Cancer 98(6):1196-205
80. 2003 Risk models for chemotherapy-induced neutropenia in non-Hodgkin's lymphoma Oncology (Williston Park) 17(11 Suppl 11):21-6
81. 2003 A clinical and scientific overview of tositumomab and iodine I 131 tositumomab Semin Oncol 30(2 Suppl 4):22-30
82. 2002 Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation Cancer J 8(5):371-6
83. 2002 Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma Blood 99(7):2554-61
84. 2002 Vaccination with CD20 peptides induces a biologically active, specific immune response in mice Blood 99(10):3748-55
85. 2002 Molecular cytogenetic analysis of genomic instability at the 1q12-22 chromosomal site in B-cell non-Hodgkin lymphoma Genes Chromosomes Cancer 35(4):318-28
86. 2002 Primary follicular lymphoma of the gastrointestinal tract: a clinical and pathologic study of 26 cases Am J Surg Pathol 26(2):216-24
87. 2001 Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma Leuk Lymphoma 42(5):1015-22
88. 2001 Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas Oncogene 20(52):7686-93
89. 2001 Establishment of a human cell line (SKI-DLCL-1) with a t(1;14)(q21;q32) translocation from the ascites of a patient with diffuse large cell lymphoma Leuk Lymphoma 40(3-4):419-23
90. 2001 Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma J Clin Oncol 19(2):389-97
91. 2001 NCCN: Non-Hodgkin's lymphoma Cancer Control 8(6 Suppl 2):102-13
92. 2001 A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model Blood 97(3):616-23
93. 2001 Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol Blood 97(7):1929-36
94. 2001 Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas J Clin Oncol 19(19):3918-28
95. 2000 Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy Leuk Lymphoma 39(1-2):67-75
96. 2000 Translocation t(14;18) in healthy individuals: preliminary study of its association with family history and agricultural exposure Ann Oncol 11 Suppl 1(75-80
97. 2000 Cloning and characterization of a Golgin-related gene from the large-scale polymorphism linked to the PML gene Genomics 70(3):364-74
98. 2000 MUC1 dysregulation as the consequence of a t(1;14)(q21;q32) translocation in an extranodal lymphoma Blood 95(9):2930-6
99. 2000 Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas J Clin Oncol 18(6):1316-23
100. 2000 Physical linkage of the lysyl oxidase-like (LOXL1) gene to the PML gene on human chromosome 15q22 Cytogenet Cell Genet 88(1-2):22-4
101. 2000 Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy Leukemia 14(9):1577-82
102. 2000 High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis Blood 96(7):2399-404
103. 2000 A novel gene STORP (STOmatin-Related Protein) is localized 2 kb upstream of the promyelocytic gene on chromosome 15q22 Eur J Haematol 64(2):104-13
104. 1999 Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma J Clin Oncol 17(12):3776-85
105. 1999 The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma Bone Marrow Transplant 23(6):561-7
106. 1999 Radioimmunotherapy for lymphoma Curr Opin Oncol 11(5):375-80
107. 1999 The W(sh), W(57), and Ph Kit expression mutations define tissue-specific control elements located between -23 and -154 kb upstream of Kit Blood 94(8):2658-66
108. 1998 Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma Clin Cancer Res 4(2):311-6
109. 1998 Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells Proc Natl Acad Sci U S A 95(1):162-6
110. 1998 Emerging role of laparoscopy in the diagnosis of lymphoma J Clin Oncol 16(5):1909-15
111. 1997 Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas Clin Cancer Res 3(2):169-77
112. 1997 Microsatellite instability in breast cancer Ann Surg Oncol 4(4):310-5
113. 1996 Derivation and characterization of retinoid-resistant human embryonal carcinoma cells Differentiation 60(4):251-7
114. 1996 The AML1/ETO fusion protein activates transcription of BCL-2 Proc Natl Acad Sci U S A 93(24):14059-64
115. 1995 The Wsh and Ph mutations affect the c-kit expression profile: c-kit misexpression in embryogenesis impairs melanogenesis in Wsh and Ph mutant mice Proc Natl Acad Sci U S A 92(9):3754-8
116. 1995 Bone marrow transplantation versus chemotherapy in non-Hodgkin's lymphoma N Engl J Med 333(11):728-9; author reply 30
117. 1995 BCL6 gene rearrangement and other cytogenetic abnormalities in diffuse large cell lymphoma Leuk Lymphoma 20(1-2):85-9
118. 1995 The PML gene is linked to a megabase-scale insertion/deletion restriction fragment length polymorphism Genomics 26(2):327-33
119. 1995 A novel L23-related gene 40 kb downstream of the imprinted H19 gene is biallelically expressed in mid-fetal and adult human tissues Hum Mol Genet 4(9):1499-507
120. 1993 W-sash affects positive and negative elements controlling c-kit expression: ectopic c-kit expression at sites of kit-ligand expression affects melanogenesis Development 118(3):705-17
121. 1993 Mucosa-associated lymphoid-tissue lymphoma N Engl J Med 329(22):1657
122. 1993 A submicroscopic interstitial deletion of chromosome 14 frequently occurs adjacent to the t(14;18) translocation breakpoint in human follicular lymphoma Genes Chromosomes Cancer 6(3):140-50
123. 1993 Pulsed-field gel electrophoresis analysis of retinoic acid receptor-alpha and promyelocytic leukemia rearrangements. Detection of the t(15;17) translocation in the diagnosis of acute promyelocytic leukemia Am J Pathol 143(5):1301-11
124. 1992 BCL2 oncogene translocation is mediated by a chi-like consensus J Exp Med 175(6):1575-88
125. 1992 Antigen selection in human lymphomagenesis Cancer Res 52(19 Suppl):5547s-51s
126. 1992 Clonal expansion in follicular lymphoma occurs subsequent to antigenic selection J Exp Med 176(4):1137-48
127. 1992 Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire Mol Immunol 29(2):193-203
128. 1992 Construction of complex directional complementary DNA libraries in SfiI Methods Enzymol 216(517-30
129. 1991 Histologic transformation of follicular lymphoma to diffuse lymphoma represents tumor progression by a single malignant B cell J Exp Med 173(1):197-207
130. 1991 Follicular lymphoma: a model of lymphoid tumor progression in man Ann Oncol 2 Suppl 2(115-22
131. 1991 Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy Blood 78(10):2768-72
132. 1991 Enhanced detection of the t(14;18) translocation in malignant lymphoma using pulsed-field gel electrophoresis Blood 78(6):1552-60
133. 1990 Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin Blood 76(11):2411-7
134. 1990 Directional cloning of cDNA using a selectable SfiI cassette Gene 89(1):123-7
135. 1987 Regulation of ribosome synthesis during compensatory renal hypertrophy in mice Am J Physiol 253(4 Pt 1):C506-13
136. 1981 Molecular cloning and characterization of the chicken gene homologous to the transforming gene of Rous sarcoma virus Cell 24(2):531-41
137. 1980 Transformation of NIH-3T3 mouse cells by avian retroviral DNAs Cold Spring Harb Symp Quant Biol 44 Pt 2(1169-76
138. 1980 Transformation by subgenomic fragments of Rous sarcoma virus DNA Cell 19(4):863-70
139. 1979 Transformation of NIH/3T3 mouse cells by DNA of Rous sarcoma virus Cell 17(4):993-1002
140. 1978 gltB gene and regulation of nitrogen metabolism by glutamine synthetase in Escherichia coli J Bacteriol 133(1):139-48
141. 1976 Circadian periodicity of epidermal growth factor and its abolition by superior cervical ganglionectomy Endocrinology 99(6):1589-96


About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.